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Public health measures successfully contained outbreaks of the severe acute respiratory syndrome coronavirus
(SARS-CoV) infection. However, the precursor of the SARS-CoV remains in its natural bat reservoir, and reemer-
gence of a human-adapted SARS-like coronavirus remains a plausible public health concern. Vaccination is a major
strategy for containing resurgence of SARS in humans, and a number of vaccine candidates have been tested in
experimental animal models. We previously reported that antibody elicited by a SARS-CoV vaccine candidate based
on recombinant full-length Spike-protein trimers potentiated infection of human B cell lines despite eliciting in vivo
a neutralizing and protective immune response in rodents. These observations prompted us to investigate the
mechanisms underlying antibody-dependent enhancement (ADE) of SARS-CoV infection in vitro. We demonstrate
here that anti-Spike immune serum, while inhibiting viral entry in a permissive cell line, potentiated infection of
immune cells by SARS-CoV Spike-pseudotyped lentiviral particles, as well as replication-competent SARS corona-
virus. Antibody-mediated infection was dependent on Fc receptor II but did not use the endosomal/lysosomal
pathway utilized by angiotensin I converting enzyme 2 (ACE2), the accepted receptor for SARS-CoV. This suggests
that ADE of SARS-CoV utilizes a novel cell entry mechanism into immune cells. Different SARS vaccine candidates
elicit sera that differ in their capacity to induce ADE in immune cells despite their comparable potency to neutralize
infection in ACE2-bearing cells. Our results suggest a novel mechanism by which SARS-CoV can enter target cells
and illustrate the potential pitfalls associated with immunization against it. These findings should prompt further
investigations into SARS pathogenesis.
Although public health measures have successfully con-
tained human outbreaks of the severe acute respiratory syn-
drome coronavirus (SARS-CoV) infection, a disease with a
case-fatality ratio of 10% (13, 32), the precursor SARS-CoV-
like virus remains endemic in its natural bat reservoir (34), and
future reemergence of a SARS-like disease remains a credible
public health threat. Therefore, efforts have continued to de-
velop safe vaccine strategies against SARS-CoV.
Neutralizing antibodies are elicited in patients recovering
from SARS and studies on experimental animal models have
shown that antibodies can prevent infection by SARS-CoV (6).
Among the four major structural SARS-CoV proteins, the
Spike envelope glycoprotein (S) has been identified as the
most important antigen inducing neutralizing and protective
antibodies (1, 3, 72). Furthermore, it has been demonstrated
that binding of Spike to its receptor angiotensin I converting
enzyme 2 (ACE2) is a key event in the entry of SARS-CoV into
cells (40).
Several vaccine strategies aiming at preventing infection by
SARS-CoV have therefore targeted the Spike glycoprotein
(14, 15). Such a strategy, however, poses concern since previ-
ous attempts at vaccination against coronaviruses have re-
sulted in markedly different outcomes. Immune protection
against animal coronaviruses, such as mouse hepatitis and
transmissible gastroenteritis viruses (11, 46), can be induced by
immunization with Spike glycoprotein. On the other hand, this
vaccine approach led to a worsened disease in the feline coro-
navirus (FCoV) infection due to the induction of infection-
enhancing antibodies (8, 25, 44, 65). Immune-mediated infec-
tions and, in particular, antibody-dependent enhancement
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(ADE) have long been known to be exploited by a variety of
viruses, such as dengue virus, HIV, and FCoV, as an alterna-
tive way to infect host cells (59, 60). In addition to interaction
between viral protein and host receptors, these viruses can
enter into cells through binding of virus/antibody immune
complexes to Fc receptors (FcR) or complement receptors or,
alternatively, by inducing a conformational change in envelope
glycoproteins that are required for virus-cell membrane fusion
(59, 60). Thus, immunization of cats with recombinant vaccinia
virus preparations expressing the FCoV Spike protein resulted
in the induction of Spike-specific antibodies responsible for an
enhanced susceptibility to challenge infection (65). The en-
hanced infection of macrophages following antibody-mediated
entry of the FCoV is responsible for the occurrence of the
severe disease feline infectious peritonitis (8, 25, 44).
We previously reported that a SARS-CoV vaccine candidate
based on recombinant, full-length SARS-CoV Spike-protein
trimers triggered infection of human B cell lines despite elic-
iting in vivo a neutralizing and protective immune response in
rodents (30). These observations prompted us to further in-
vestigate the molecular and cellular mechanisms underlying
ADE of SARS-CoV infection in vitro.
By monitoring the susceptibility of immune cell lines having
different patterns of Fc receptor (FcR) expression, we have
demonstrated the predominant role of human FcRII (CD32)
in mediating ADE of SARS-CoV. Furthermore, we have pro-
vided evidence that, in contrast to the ACE2-mediated infec-
tion, ADE pathways are independent of endosomal or lyso-
somal pH and are minimally affected by the activities of
cysteine proteases. Finally, we have found marked differences
between different SARS vaccines in their capacity to elicit a
humoral immune response that neutralizes or facilitates infec-
tion by SARS-CoV in vitro, an observation that should prompt
further studies to develop safe immunization protocols.
MATERIALS AND METHODS
Cell lines. The following cell lines were used in the present study: VeroE6
(African green monkey kidney epithelial cells), K-562 (human chronic myelog-
enous leukemia cells), U-937 (human histiocytic lymphoma cells), THP-1 (hu-
man acute monocytic leukemia cells), SUP-T1 (human lymphoblastic leukemia/T
lymphoblast), MOLT-3 (human acute lymphoblastic leukemia/T lymphoblast),
MT4/R5 (human T cell lymphoblast expressing CCR5), Raji (Burkitt’s lympho-
ma/B lymphoblast), Daudi (Burkitt’s lymphoma/B lymphoblast), parental ST486
(Burkitt’s lymphoma/B lymphoblast lacking expression of FcR) and FcR/
ST486, 721.221 (Epstein-Barr virus-transfected human B cells), and P388D1 and
J774A.1 (murine macrophage-like lymphoblasts). VeroE6 cells were cultured in
Dulbecco modified Eagle medium (DMEM) supplemented with 10% of heat-
inactivated fetal bovine serum (FBS), and hematopoietic cells were cultured in
RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 1% nones-
sential amino acids, 4 mM L-glutamine, 1 mM sodium pyruvate, and 20 M
2-mercaptoethanol (all from Invitrogen). All cells were maintained in a humid-
ified atmosphere at 37°C with a 5% CO2 supply.
Immunization with recombinant Spike proteins or inactivated SARS-CoV.
Recombinant SARS-CoV Spike proteins were produced as described elsewhere
(4, 30). Six to eight-week-old BALB/c mice (n  4 to 5 per group) were immu-
nized intraperitoneally with one of the following antigens: 2 g of recombinant
codon-optimized SARS-CoV Spike full-length (S, amino acids [aa] 1 to 1255), 2
g of recombinant codon-optimized SARS-CoV Spike ectodomain (S.ECD, aa
1 to 1184), 2 g of recombinant codon-optimized SARS-CoV Spike subunit 1
(S1, aa 1 to 757), or 10 g of recombinant, soluble SARS-CoV Spike truncated
early after the transmembrane domain (Ssol, aa 1 to 1193) (see Fig. 8A for
details). All recombinant proteins were FLAG tagged according to standard
molecular biology techniques. An additional group, immunized with 2 g (Spike-
equivalent) of gamma-irradiated SARS-CoV virion (60Co based, 50 KGy; whole
killed virus [WKV]), was also included, as well as a control group injected with
saline solution. Mice received two immunizations in the presence of 1 mg of
Alum at 3-week intervals, and blood samples were collected by bleeding the
saphenous vein on days 1, 27, and 55 postimmunization in accordance with
local guidelines for animal handling. For all groups (n  4 to 5), serum samples
were collected at day 55 postimmunization, and an equal volume from each
animal was pooled, heat inactivated for 30 min at 56°C, and stored at 20°C for
subsequent use.
Production and use of lentiviral pseudotyped particles. The pseudotyped viral
particles expressing a luciferase reporter gene were essentially produced as
described elsewhere (42). Briefly, SARS-CoV Spike-pseudotyped lentiviral par-
ticles (SARS-CoVpp), vesicular stomatitis virus glycoprotein (VSV-G)-pseu-
dotyped lentiviral particles (VSVpp), or lentiviral particles lacking expression of
any viral envelope protein (env.pp) were obtained by transfection of HEK293T
cells with an HIV-1 provirus construction (pNL4.3.LucREpro) and a plas-
mid encoding the viral envelope protein of interest, i.e., SARS-CoV Spike,
VSV-G, or empty vector (pcDNA3.1; Invitrogen), respectively. After a purifica-
tion step on a 20% sucrose cushion, the concentrated viral particles were titrated
by enzyme-linked immunosorbent assay (ELISA) for lentivirus-associated HIV-1
p24 protein according to the manufacturer’s instruction (Cell Biolabs, Inc.), and
the viral stocks were stored at 80°C until use.
For neutralization and ADE assays, 100 l of serial, 2-fold dilutions of heat-
inactivated mouse serum were incubated for 1 h at 37°C with 100 l of pseu-
dotyped viral particles. The same inoculum was then used to infect in parallel
both VeroE6 (SARS-CoVpp neutralization test) and hematopoietic (ADE as-
say) cells. Briefly, 104 VeroE6 cells were seeded 24 h before the infection in a
96-well Opti-plate (Perkin-Elmer). On the day of infection, the cells were washed
twice, and 25 l of inoculum was added to an equivalent volume of supplemented
DMEM. Hematopoietic cells were washed and diluted to 2  106 cells/ml in
supplemented RPMI 1640 medium. Portions (25 l) of inoculum were deposited
in a 96-well Opti-plate, and an equal volume of the cell suspension was added
immediately thereafter. After 1 h of incubation at 37°C, the cells were washed
and incubated for additional 65 to 75 h in 100 l of supplemented culture
medium. The cells were quenched by adding 100 l of BrightGlow luciferase
substrate (Promega) directly to each well, and the luciferase activity was mea-
sured with a MicroBeta Jet counter (Perkin-Elmer). Background values, moni-
tored from uninfected cells and cells infected with lentiviral particles lacking
expression of any viral envelope protein (env.pp) were consistently below 200
relative luminescence units (see Fig. 1 for reference).
Infection with SARS-CoV. Serial, 2-fold dilutions of heat-inactivated mouse
sera were incubated for 1 h at 37°C with an equal volume of live SARS-CoV
(strain HKU-39849) under appropriate containment in a BSL3 laboratory (De-
partment of Microbiology, The University of Hong Kong). Both VeroE6 and
Raji cells were infected at a multiplicity of infection (MOI) of 1 for 60 min at
37°C, washed, and then incubated in supplemented culture medium containing
appropriate dilutions of mouse serum. At the end of the experiment, the cells
were either fixed in 4% paraformaldehyde (dissolved in phosphate-buffered
saline) for immunofluorescence microscopy or resuspended in lysis buffer (RLT
buffer, RNeasy RNA minikit; Qiagen) for endpoint and real-time quantitative
PCR and stored appropriately until use. In addition, samples of the cell culture
supernatants (100 l) harvested at different time points were mixed with 350 l
of RLT buffer and stored at 80°C until use.
Immunofluorescence microscopy. To assess SARS-CoV infection, both
VeroE6 and Raji cells were incubated for 45 min with either a mouse monoclonal
antibody specific for the viral nucleoprotein (N) (7) or rabbit polyclonal anti-
bodies recognizing the viral membrane (M) protein (ProSci), which were re-
vealed by secondary TRITC (tetramethyl rhodamine isothiocyanate)-conjugated
goat anti-mouse (Zymed Laboratories) and fluorescein isothiocyanate (FITC)-
conjugated goat anti-rabbit antibody (Jackson Immunoresearch), respectively.
Slides were assembled with DAPI (4,6-diamidino-2-phenylindole)-containing
mounting reagent (Southern Biotech) and analyzed with an AxioObserver Z1
microscope (Zeiss). Pictures from 10 to 30 randomly selected fields were ac-
quired with an Axiocam MRm camera and processed with MetaMorph software
(Molecular Devices).
Endpoint and real-time quantitative reverse transcriptase PCR (RT-PCR) for
viral gene expression. Total RNAs were extracted with an RNeasy RNA minikit
(Qiagen), with DNase digestion, according to the manufacturer’s instructions.
Extracted RNAs were stored at 80°C until use. Superscript III reverse trans-
criptase (Invitrogen) and random hexamer primers (Invitrogen) or gene-specific
oligonucleotides were used to convert RNAs to cDNAs. The amounts of viral
and host RNA were measured either by conventional endpoint PCR or by
real-time quantitative PCR using TaqMan MGB probe-based technology on a
LightCycler 480-II instrument (Roche). The primers and conditions for detection
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of the GAPDH and SARS-CoV genomic and subgenomic species (18), as well as
the SARS-CoV ORF1b and nucleoprotein genes (7), have been described pre-
viously. Positive and negative controls were included in each run and, when
appropriate, the levels of SARS-CoV gene expression were normalized to those
of the 18S rRNA gene, which were determined using 600 nM concentrations of
both forward (5-CggAggTTCgAAgACgATCA-3) and reverse (5-ggCgggTCA
TgggAATAAC-3) primers and a 100 nM concentration of the probe (5HEX-
ATACCgTCgTAgTTCCgACCA-BHQ3).
Human Fc receptor profiling by conventional endpoint PCR. Total RNAs
were extracted with an RNeasy RNA minikit (Qiagen), with DNase digestion,
according to the manufacturer’s instructions, and stored at 80°C until use.
Superscript III reverse transcriptase (Invitrogen) and random hexamer primers
(Invitrogen) were used to convert RNAs to cDNAs. Additional samples consist-
ing of negative RT controls (RT) were prepared by omitting Superscript III
during reverse transcription. The amounts of RNA/cDNA encoding FcεR1
chain, FcRIA (CD64a), FcRIIA (CD32a), FcRIIB (CD32b), FcRIIIA
(CD16a), ACE2, and GAPDH were measured by conventional endpoint PCR
using the primer pairs described in Table 2. Negative and positive controls (i.e.,
DNA plasmid containing the full coding sequence of the gene of interest) were
included in each run. The amplification procedure consisted of an initial dena-
turation step at 94°C for 5 min, followed by 30 cycles of three steps of 45 s each,
including denaturation at 94°C, primer annealing at 60°C, and primer extension
at 72°C. The protocol also included a final extension step at 72°C for 7 min.
Amplicons were eventually visualized by ethidium bromide staining after elec-
trophoresis in 2% agarose gel, and negative images were taken.
Flow cytometry. Cells were harvested at 4°C in phosphate-buffered saline
containing 1% FBS, 2% normal human serum, 3% normal goat serum, 2 mM
EDTA, and 0.1% sodium azide and then incubated for 30 to 45 min at 4°C with
1 g of either isotype-matched control or monoclonal antibody/ml for the indi-
cated human FcR. The following mouse monoclonal antibodies were used: 3G8
anti-hCD16, 3D3, FLI8.26 anti-hCD32, or 10.1 anti-hCD64 (all from BD Phar-
mingen) and MOPC-21 (IgG1, 	) or MPC-11 (IgG2b, 	) isotype controls (both
from BioLegend). The cells were then washed, and the primary antibody binding
was revealed by staining at 4°C for 30 min with FITC-conjugated goat anti-mouse
antibodies (Jackson Immunoresearch). Finally, washed cells were further incu-
bated with an optimal concentration of the fixable viability dye eFluor 660
(FVD660; eBioscience). The data were collected from30,000 singlet living cells
on a LSRII flow cytometer (BD Biosciences), and postacquisition analyses were
performed using the FlowJo software (TreeStar).
Blockade of human Fc receptor in vitro. Cells were washed with cold, sup-
plemented RPMI 1640 medium and maintained on ice throughout the anti-FcR
blocking step only. Briefly, 2  105 cells were treated for 45 to 60 min in 200 l
of supplemented culture medium containing 5 g of either FcR-specific mouse
monoclonal antibody (3G8, anti-hCD16; FLI8.26, anti-hCD32; and 10.1, anti-
hCD64 [BD Pharmingen]) or isotype-matched controls (clone MOPC-21 and
MPC-11 [BioLegend])/ml. An equal volume of inoculum was directly added to
the tubes, and the samples were incubated at 37°C for 60 min. Cells were washed
twice and resuspended in supplemented culture medium (5  105 cells/ml), and
100 l (triplicate) was transferred to a 96-well Opti-plate (Perkin-Elmer). The
plates were then incubated at 37°C for 65 to 75 h, and the luciferase activity was
measured as described above.
Lentiviral transfer vector construction. We constructed the lentiviral plasmids
encoding human FcεR-chain and/or human FcR by substituting enhanced
green fluorescent protein (eGFP) and/or hygromycin resistance gene from the
bicistronic vector pCHMWS-eGFP_IRES_hygromycin (kindly provided by Rik
Gijsbers and Zeger Debyser [Katholieke Universiteit Leuven, Leuven, Bel-
gium]). The FcεR-chain coding sequence (GenBank accession no. M33195) was
obtained by PCR amplification from the huFcR/pBJ1 neo plasmid (kindly
provided by Jean-Pierre Kinet [Harvard Medical School, Boston, MA]) (38). The
unique restriction sites BamHI and XhoI were added to the 5 and 3 ends,
respectively. After amplification, the human FcεR-chain PCR product was
digested with BamHI and XhoI and inserted into the transfer plasmid to yield
pCHMWS-huFcεR-chain_IRES_hygromycin. The latter construction was used
to generate pCHMWS-huFcεR-chain_IRES_huFcRIA and pCHMWS-
huFcεR-chain_IRES_huFcRIIIA.
The human FcRIA (hCD64a) coding sequence (GenBank accession no.
NM_000566) was obtained by PCR amplification from the huFcRIA/pcDNA-1
plasmid (kindly provided by Clark L. Anderson, Ohio State University, Colum-
bus, OH) (41), with BamHI and SpeI linkers at the 5 and 3 ends, respectively.
After amplification, the human FcRIA PCR product (1,151 bp) was digested
with BamHI and SpeI and inserted into the transfer plasmid digested by BclI and
SpeI to yield pCHMWS-huFcεR-chain_IRES_huFcRIA. A human FcRIIIA
(hCD16a) fragment (1,417 bp) was removed from the LL649 plasmid (kindly
provided by Lewis L. Lanier, University of California, San Francisco, CA) (33)
using BamHI and EcoRI and inserted into the pIRES plasmid (Clontech) using
the same restriction enzymes. A cDNA fragment (183 bp) was PCR amplified
from human peripheral blood mononuclear cells using the forward (5-TgACgg
ATCCAggAAATTggTgggTgACAg-3) and reverse (5-gTCAggATCCTAgCAg
AgCAgTTgggAggA-3) primers, both flanked by an BamHI site, and then inserted
into LL649/pIRES plasmid at the BamHI site. The full human FcRIIIA coding
sequence (GenBank accession no. NM_000569) was generated by excision of the
undesirable fragment (225 bp) with EcoRV and direct religation, yielding the
huFcRIIIA/pIRES shuttle vector. The human FcRIIIA fragment was subse-
quently excised using BamHI and NcoI
Klenow blunting and cloned into the
lentiviral vector resulting in pCHMWS-huFcεR-chain_IRES_huFcRIIIA. Coding
sequences for human FcRIIA (hCD32a) isoforms (huFcRIIA.R131 and
huFcRIIA.H131 GenBank accession no. NM_021642) and human FcRIIB1
(hCD32b; GenBank accession no. AF543826) flanked by BglII and SalI sites were
commercially synthesized (GeneArt, Regensburg, Germany). The synthetic se-
quences were digested by BglII and SalI and inserted into the original transfer
plasmid to yield pCHMWS-huFcRIIA.R131_IRES_hygromycin, pCHMWS-
huFcRIIA.H131_IRES_hygromycin, and pCHMWS-huFcRIIB1_IRES_
hygromycin. To verify that PCR amplification and cloning procedures had not
introduced random mutations, all constructs were sequenced by the Genome
Research Centre (The University of Hong Kong).
Generation of FcR-expressing cell lines using lentiviral particle-based gene
transduction. Pseudotyped viral particles were essentially produced as described
elsewhere (42). Briefly, VSV-G-pseudotyped lentiviral particles were obtained by
transfecting HEK293T cells with a packaging plasmid (pCMVR8.91), a plasmid
encoding the envelope of VSV (pCI-VSVg), and a pCHMWS-derived transfer
plasmid (described above) coding for a human Fc receptor as specified. Stable
cell lines were generated by the transduction of monoclonal ST486 cells with the
VSV-G-pseudotyped lentiviral particles. Briefly, target cells were washed and
diluted to 3  106 cells/ml in supplemented RPMI 1640 medium. One milliliter
of crude supernatant from pseudoparticle-producing 293T cells was deposited in
a 24-well plate, and an equal volume of the cell suspension was added immedi-
ately thereafter. After 3 to 8 h of incubation at 37°C, the cells were washed and
incubated for additional 40 to 48 h in 2 ml of supplemented culture medium. At
2 days postinfection, the cell surface expression of the human FcR was moni-
tored by flow cytometry, and the cells were subsequently cultured in selective
medium containing 250 g of hygromycin (Invitrogen)/ml when appropriate.
Finally, several monoclonal cell lines for each construct were isolated by Pois-
FIG. 1. Susceptibility of hematopoietic cell lines to infection by SARS-CoV Spike pseudoparticles (SARS-CoVpp). (A) SARS-CoVpp were incu-
bated in the presence or absence of different dilutions (1/1,000, 1/2,000, and 1/4,000) of either control (solid bars) or anti-Spike (hatched bars) serum for
1 h prior to addition to the cells. At 3 days postinfection, luciferase substrate reagent was added to wells, and the luminescence was measured. The data
were normalized to control conditions, viz., cells incubated with SARS-CoVpp in the absence of any serum (taken as unity), and are expressed as the fold
changes in luminescence. Because the results for SARS-CoVpp with or without control serum were virtually identical with all cell lines, for the sake of
clarity only one dilution (1/4,000) is shown. The results are the means  the SD of six measurements from two independent experiments. Statistical
significance was assessed by comparing the appropriate dilutions of control and anti-Spike serum (‡, P  0.05; *, P  0.001 [unpaired Student t test]).
(B to D) HIV Gag-normalized lentiviral particles (0.1 ng of p24 protein/l) pseudotyped with the envelope glycoprotein of SARS-CoV Spike
(SARS-CoVpp [B]) or vesicular stomatitis virus (VSVpp [C]) or lacking any viral envelope protein (env.pp [D]) were incubated in the presence or
absence of a 1/1,000 dilution of either control (solid gray bars) or anti-Spike (hatched bars) serum for 1 h prior to addition to the cells. At 3 days
postinfection, luciferase substrate reagent was added, and the luminescence was measured. The results are the means  the SD of nine measurements
from three independent experiments. When not visible, the SD values were contained within the size of the symbols. Anti-Spike serum either significantly
decreased (VeroE6) or increased (THP-1, Raji, and Daudi) entry of SARS-CoVpp. *, P  0.001 (unpaired Student t test).
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son’s limiting dilution procedure, and expression of the transgene was confirmed
by RT-PCR (data not shown) and flow cytometry (see Fig. 6A).
Lysosomotropic agent and protease inhibitor treatments. Cells were preincu-
bated with the indicated amounts of drugs, either ammonium chloride (NH4Cl)
or E-64d/cathepsin L inhibitor (Cat L Inh; Calbiochem), for 1 h or 3 h prior to
infection, respectively. SARS-CoVpp, pretreated with immune or control serum,
were mixed with the same concentrations of drugs in tubes and added to the cells.
After 5 h (E-64d or Cat L Inh) or 7 h (NH4Cl), the cells were washed and further
incubated with fresh medium without any drug. Cells were assayed for luciferase
activity 60 to 65 h after infection, as described above.
Statistical analysis. Results are shown as means  the standard deviations
(SD) of the indicate number of observations. The statistical difference between
groups was determined by using an unpaired Student t test with a 0.05 signifi-
cance level.
RESULTS
Anti-Spike immune serum promotes the infection of human
hematopoietic cells by SARS-CoV. SARS-CoV-induced pa-
thology is not confined to the respiratory tract but also involves
other tissues and organs, most importantly cells of the gastro-
intestinal tract and the immune system (19, 39, 74). Although
several reports have shown that SARS-CoV can infect hema-
topoietic cells, it is not known how the virus gets a foothold
into these immune cells that do not express the specific SARS-
CoV receptor ACE2 (20, 21).
In order to investigate the possibility of antibody-mediated
infection of immune cells during SARS pathogenesis, we have
taken advantage of SARS-CoV Spike-pseudotyped particles
(SARS-CoVpp) to compare the effect of anti-Spike immune
serum on the prototypic permissive VeroE6 cells and a panel
of immune cell lines (Fig. 1A). These recombinant viruses
encoding a reporter gene and bearing the SARS-CoV Spike
protein at the virion surface have been shown to faithfully
mimic the SARS-CoV entry process (57, 71). As expected,
SARS-CoVpp efficiently infected VeroE6 cells, whereas the
luminescence signal detected in any of the immune cell types
never exceeded values measured in the absence of SARS-
CoVpp (Fig. 1B). To explore the occurrence of antibody-me-
diated infection, we preincubated SARS-CoVpp with either
mouse anti-Spike immune-serum (Fig. 1A and B, hatched
bars) or control serum (Fig. 1A and B, solid gray bars) prior to
infection and then compared the resulting luminescence signal
intensities.
The outcome of infection with SARS-CoVpp in the pres-
ence of anti-Spike immune-serum depended on the target cell
type. Although heat-inactivated serum inhibited SARS-CoVpp
entry into the permissive VeroE6 cell line in a dose-dependent
fashion, as demonstrated by a dramatic drop in the intensity of
luminescence (Fig. 1A and B, hatched bars), it facilitated in-
fection of the human monocytic cell line THP-1 and of the B
cell lines Daudi and Raji. In contrast, no infection of these cell
lines was noticed when SARS-CoVpp were preincubated with
control serum (Fig. 1A and B, solid bars), and similar back-
ground levels of luminescence were detected in the presence of
immune serum only (data not shown). Of note, infection of the
THP-1, Raji, and Daudi cell lines by recombinant viral parti-
cles pseudotyped with the glycoprotein of the vesicular stoma-
titis virus (VSVpp; Fig. 1C) or no viral envelope protein
(env.pp; Fig. 1D) was never affected by the presence of anti-
SARS-CoV Spike immune serum. These experiments indicate
that anti-Spike antibodies facilitate infection of SARS-
CoVpp—but not VSVpp or env.pp—into distinct immune
cell types.
Altered tropism of replication-competent SARS-CoV toward
human immune cells in the presence of anti-Spike immune
serum. Because Raji cells displayed the greatest susceptibility
to antibody-mediated infection of SARS-CoVpp (Fig. 1A and
B), we used this B-cell-derived human cell line to investigate
whether a change of tropism could also be observed during
infection with replication-competent SARS-CoV.
As reported previously (30), infection of permissive VeroE6
cells remained unchanged in the presence of control serum,
whereas anti-Spike immune serum fully abrogated it (Fig. 2A).
In contrast, when Raji cells were infected in the presence of
anti-Spike immune-serum, detection of intracellular viral pro-
teins (viz., membrane and nucleocapsid) was markedly differ-
ent from those infected in the presence of control serum (Fig.
2B). Such enhanced infection was also demonstrated at the
molecular level, since the viral gene detection by conventional
RT-PCR (i.e., endpoint PCR; Fig. 3A) fully paralleled the
real-time quantitative PCR measurements (Fig. 3B). Com-
pared to inoculum containing control serum, there was signif-
icantly enhanced detection of subgenomic viral RNA (sgRNA)
and nucleocapsid genes observed in Raji cells infected in the
presence of anti-Spike immune serum (Fig. 3B, P  0.001).
Although we never detected SARS-CoV proteins in cells chal-
lenged in the presence of control serum, trace amounts of PCR
products related to SARS-CoV ORF1b (data not shown), nu-
cleocapsid genes and other viral genomic and subgenomic
RNA were detectable (Fig. 3). These background levels were
likely the result of nonspecific binding/uptake of SARS-CoV.
Taken together, these experiments indicate that anti-Spike se-
rum can trigger infection of immune cells by live SARS-CoV,
similarly to that observed with the pseudotyped viral particles.
Antibody-mediated enhancement of SARS-CoV infection in
Raji cells leads to abortive infection. To assess the capability of
SARS-CoV to productively replicate into ADE-infected Raji
cells, we monitored by PCR the cellular viral load, as well as
the release of SARS-CoV progeny into cell culture superna-
tant. As previously seen at 15 hours postinfection (hpi) (Fig.
3A), all samples were determined to be positive by endpoint
PCR for the detection of SARS-CoV genomic RNA. At most
of the time points, low but noticeably higher amounts of
SARS-CoV sgRNA were visible in cells infected in the pres-
ence of anti-Spike serum (not shown). Such results are in
accordance with the quantitative measurements of either pos-
itive (i.e., genomic and mRNA) or negative (i.e., subgenomic
replicative intermediates) RNA strands, demonstrating an in-
creased viral load at 6 hpi, followed by a continuing decrease of
both viral RNA species with time so that no more difference
between groups was noted later on (Fig. 4A). Interestingly,
despite the detection of SARS-CoV nucleic acid, neither
SARS-CoV membrane (not shown) nor nucleocapsid protein
(Fig. 4B) were detected in cells infected in the absence or
presence of control serum. In contrast, a significant percentage
of SARS-CoV nucleocapsid protein-positive cells was visual-
ized when infected in the presence of anti-Spike serum, al-
though there was no evidence of productive virus replication
and spread to infect other cells (Fig. 4B).
To allow multiple antibody-mediated infection cycles, cells
were cultured in the continuous presence of control or anti-
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Spike serum. Because anti-Spike immune serum neutralized
infection of permissive ACE2-bearing cells, it was not possible
to titrate supernatants for infectious virus by 50% tissue cul-
ture infective dose (TCID50) titration or plaque assays. Thus,
real-time RT-PCR quantification of SARS-CoV viral genes in
the culture supernatants was the only option available. As
expected, we observed a concentration-dependent increase in
the detection of both SARS-CoV ORF1b- and N-genes when
supernatants of known TCID50 titers were measured (Tables 1
and 2). Likewise, we detected increasing viral gene copies in
cell culture supernatants of VeroE6 cells from 
 1 to 7 to 9
days postinfection. Whereas the presence of control serum did
not affect the virus titer, infection in the presence of anti-Spike
immune serum significantly decreased it (log10 values of the
nucleocapsid gene copies  the SD at 9 days postinfection:
SARS-CoV [6.22  0.07] versus SARS-CoV 
 1/1,000 control
serum [5.88  0.07] versus SARS-CoV 
 1/1,000 anti-S serum
[0.54 0.13]). In contrast, we did not detect any change in viral
gene copies when we assessed the viral load in supernatants of
Raji-infected cells, whether incubated in the presence or ab-
sence of immune serum (Table 1).
Altogether, these results indicate that despite the ability of
SARS-CoV to exploit antiviral antibodies to invade Raji B
cells, only abortive replication occurs upon infection, and no
infectious virus is released from the ADE-infected Raji cells.
The occurrence of ADE of SARS-CoV infection relies on the
expression of human FcRII (CD32) by the target cells. ADE
involves several mechanisms, mostly through Fc receptor(s)
(FcR) and complement receptor(s) (CR). Since ADE of
SARS-CoV infection in our experimental setting occurred in
the presence of heat-inactivated serum, we did not further
investigate the contribution of CR to the observed phenome-
non but, rather, focused on the possible participation of FcR,
which are expressed on the human leukocytes (9, 49).
Because we had previously shown the participation of
FcRII in antibody-mediated infection of Raji B cells (30), we
examined by RT-PCR the expression profile of all the hema-
topoietic cell lines tested for susceptibility to antibody-medi-
ated infection of SARS-CoVpp (Fig. 5A). The human immune
cell lines displaying a detectable level of FcR transcript were
then subjected to flow cytometry (Fig. 5B). Our results indicate
that U-937 and THP-1 exhibited cell surface expression of both
FcRI and FcRIIA. As ascertained by RT-PCR, they express
both the membrane-bound and the soluble isoforms of
FcRIIA (17, 66). The other cells express a single FcR, ex-
cept SUP-T1, MOLT-3, and ST486 (two T cell lines and a B
cell line, respectively), which do not show detectable levels of
any FcR. Expression of FcRIIA was detected in K-562 cell
line, whereas the others predominantly display FcRIIB. Of
note, additional faint bands for the FcRIIA were also seen in
Raji cells (Fig. 5A and B).
Because THP-1, Raji, and Daudi cells are susceptible to
ADE infection (Fig. 1) and because they express cell surface Fc
receptor (Fig. 5), we investigated the effect of blocking indi-
vidual FcR on the occurrence of ADE infection (Fig. 5C).
Although treatment with anti-FcRI or anti-FcRIII blocking
antibody had virtually no effect on ADE in Raji and Daudi
cells, blocking of FcRII fully abrogated ADE infection of
these cells. For THP-1, not only anti-FcRII treatment de-
creased ADE infection, as expected, but also FcRI (Fig. 5C).
THP-1 cells indeed express both FcRI and FcRII, and intact
antibodies could bind to the targeted FcR via their Fab por-
FIG. 2. Anti-Spike antibodies trigger SARS-CoV infection of human Raji B cells. VeroE6 or human Raji cells were infected (MOI  1) with
SARS-CoV strain HK39849 (SCoV) in the presence of either control or Anti-Spike serum for 1 h. Samples were fixed with 4% paraformaldehyde
at 15 h postinfection. A mouse monoclonal antibody specific for the SCoV nucleocapsid (N) and rabbit polyclonal antibodies specific for SCoV
membrane (M) protein were visualized using TRITC-conjugated goat anti-mouse and FITC-conjugated goat anti-rabbit antibodies, respectively.
Cell nuclei were labeled with DAPI, and separate channel images were acquired. (A) As expected, SCoV infection of VeroE6 (I) was completely
blocked by anti-Spike serum (1/500, II). (B) In contrast, SCoV viral proteins were detected in Raji cells only when they were incubated with
anti-Spike (1/500, IV) but never with control serum (III). Quantification of infection (right-hand portions in panels A and B) was done by counting
positive cells in 30 randomly chosen fields (630, final magnification), using Metamorph as described in Materials and Methods. The results are
shown as means  the SD of the number of fields.
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tions and also to other FcR expressed by the same cells via
their Fc portion. Supporting this interpretation, anti-FcRI is
a mouse IgG1 that binds well to FcRII, whereas anti-FcRII
is a mouse IgG2b that binds less efficiently to FcRI (M.
Dae¨ron et al., unpublished observations).
To further establish the specific role of the FcR subfamily
in the ADE phenomenon, we stably transduced the ST486 B
cell line, which is naturally deficient in the expression of the
FcR, with different constructs coding for FcRIA (CD64a),
FcRIIA (CD32a), FcRIIB1 (CD32b), and FcRIIIA
(CD16a). Moreover, due to allelic polymorphism of the human
FcRIIA and its alleged implications in disease susceptibility
(48), we generated two variants of FcRIIA bearing either a
histidine (H) or an arginine (R) at amino acid position 131. As
shown in Fig. 6, the parent ST486 cells were insensitive to both
direct and antibody-mediated infection. Transduction of
ST486 cells by lentiviral particles containing the different FcR
coding sequences led to the generation of stable cell lines
highly expressing the mRNA transgene (not shown), as well as
the encoded FcR at the plasma membrane (Fig. 6A). Simi-
larly to the parental ST486 cells, FcR-expressing cells were
not permissive to direct SARS-CoVpp infection, regardless of
their receptor subtype (Fig. 6B). However, when cells were
infected in the presence of anti-SARS-CoV Spike immune-
serum (Fig. 6B, hatched bars), ST486 expressing FcRII be-
came susceptible to antibody-mediated infection. Although
both FcRII members—FcRIIA and FcRIIB1—mediated
enhanced SARS-CoVpp immune complex infectivity, we
found that FcRIIA appeared to do so more efficiently. Both
FcRIA and FcRIIIA were unable to mediate ADE despite
the wide range of serum dilutions that were tested (Fig. 6B).
Antibody-mediated infection by SARS-CoV does not rely on
pH- and protease-dependent entry pathways. To compare the
cellular requirements of ACE2- and FcR-mediated infection
pathways, we investigated the effect of treatments with lysoso-
motropic agent and protease inhibitors on ADE. As previously
described (24, 71), the addition of ammonium chloride
(NH4Cl), which prevents acidification of endosomal/lysosomal
compartments, caused a dose-dependent reduction of SARS-
CoVpp infection in ACE2-expressing VeroE6 cells (Fig. 7A,
black squares). Similar treatment of Raji cells did not inhibit,
but instead further enhanced antibody-mediated infection of
FIG. 3. Endpoint and real-time PCR detection of SARS-CoV genes in ADE-infected Raji cells. (A) VeroE6 and human Raji cells were
incubated for 1 h in the absence (mock) or presence of SARS-CoV strain HK39849 (SCoV), with either control or anti-Spike (S) serum as
indicated. The cells were lysed at 15 h postinfection, and total RNAs were extracted for RT-PCR amplification as described in Materials and
Methods. Amplicons were visualized by ethidium bromide staining after agarose gel electrophoresis. A 1-kb molecular weight standard is shown
on the left lane of each gel. (B) From the cDNA samples prepared in panel A, the levels of SCoV nucleocapsid and SCoV ORF1b (not shown)
genes were determined by real-time quantitative RT-PCR. Raji cells were consistently infected in the presence of serial dilutions (1/250 to 1/4,000
in 2-fold dilutions) of anti-Spike serum that, in contrast, inhibited in dose-dependent fashion viral entry into the susceptible VeroE6 cells. The data
are shown as the means  the SD of four measurements from duplicate cultures and are representative of three independent experiments with
similar results. **, P  0.001 (unpaired Student t test).
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SARS-CoVpp (Fig. 7A, red circles). Incubation of VeroE6
cells with both the broad cysteine protease inhibitor E-64d, as
well as the more specific cathepsin L inhibitor III, abrogated
ACE2-mediated infection (26, 56) (Fig. 7C and D, black
squares), whereas E-64d did not have any impact on the ADE
pathway, and only a partial reduction of ADE of SARS-CoVpp
was observed in Raji with the highest tested concentrations of
cathepsin L inhibitor III (Fig. 7C and D, red circles).
In these experiments, we noticed that neutralization of the
endosome/lysosome acidification enhanced the infectivity of
anti-Spike immune-serum-treated SARS-CoVpp (Fig. 7A, red
circles). This observation raised the possibility that alkaliniza-
tion of cells was associated with an increased expression of
FcR at the cell surface. Because Raji cells only express
FcRII (Fig. 5 and 6), we explored its expression levels at the
cell surface after treatment with ammonium chloride. Our data
indicate that surface expression of FcRII was not increased
(but, rather, slightly decreased) at 1, 3, and 5 h postinfection in
the presence of NH4Cl (Fig. 7B). Together, these results dem-
onstrate that the two receptor-mediated infection processes,
via ACE2 and FcRII, follow very distinct cellular pathways.
Immune sera elicited by different SARS vaccine candidates
mediate distinctly different profiles of virus neutralizing or
enhancing activity. The SARS-CoV Spike glycoprotein, shown
to be responsible for receptor binding to cellular ACE2, has
been hypothesized to be a promising target for the develop-
ment of both vaccines and therapeutics (14). Because we pre-
viously reported that anti-Spike sera can trigger SARS-CoV
FIG. 4. Abortive replication of SARS-CoV in Raji cells following antibody-mediated infection. (A) Human Raji cells were incubated for 1 h
in the absence or presence of SARS-CoV strain HK39849 (SCoV), with 2-fold serial dilutions (1/250 to 1/4,000) of either control or anti-Spike
(S) serum. Cells were lysed at 6, 24, 48, and 72 hpi, and total RNAs were extracted and reverse transcribed into sense-specific cDNA species as
described in Materials and Methods. The levels of positive (
) and negative () SCoV nucleocapsid strands were determined by real-time
quantitative RT-PCR. For the sake of clarity, only one serum dilution (1/1,000) is shown. At an early time point (6 hpi), a high viral load was
consistently detected in cells infected in the presence of anti-Spike but not in control serum. At later times (24 to 72 hpi), no further difference
among the treatments was noticeable. The data are shown as means  the SD of four measurements. When not visible, the SD values were
contained within the size of the symbols. **, P  0.001 (unpaired Student t test). (B) Human Raji cells infected as indicated in panel A were fixed
with 4% paraformaldehyde, and costaining for SCoV nucleocapsid and cell nuclei was performed as described in Materials and Methods.
Quantification of the infected and uninfected cells was done by counting 10 randomly chosen fields using Metamorph software. For the sake of
clarity, results for only one serum dilution (1/1,000) are shown. Cell numbers and related percentage of infection are shown as means  the SD
of the number of observations. SCoV infection of Raji cells occurred only in the presence of anti-Spike serum, but the percentage of infected cells
did not significantly increase over time.
TABLE 1. Viral yield in culture supernatants of SARS-CoV-infected Raji cells
Sample and treatment Time (h)postinfection
Viral titer
(log10 TCID50/ml)
Mean no. (log10)  SD
ORF1b gene copies Nucleocapsid gene copies
SARS-CoV inoculum (no treatment) 3 3.28  0.04 3.41  0.07
5 5.39  0.04 5.51  0.08
6 6.76  0.05 6.94  0.07
Cell culture supernatant from Raji cells
No treatment 6 to 72 NDa 0 0
SARS-CoV 
 1/1,000 control serum 6 ND 3.05  0.15 3.56  0.37
24 ND 3.24  0.13 3.84  0.46
48 ND 3.10  0.03 3.50  0.53
72 ND 3.30  0.04 3.65  0.43
SARS-CoV 
 1/1,000 anti-S serum 6 ND 3.36  0.14 3.89  0.41
24 ND 2.84  0.14 3.46  0.50
48 ND 3.26  0.04 3.67  0.50
72 ND 3.43  0.03 3.73  0.38
a ND, not determined. The TCID50 titration was not possible due to the presence of neutralizing immune serum in some cell culture supernatants. Results are shown
as means  the SD of four samples from two independent measurements.
VOL. 85, 2011 IMMUNE-MEDIATED ENHANCEMENT OF SARS-CoV INFECTION 10589
 o
n
 February 25, 2014 by BRUNEL UNIV SERVICES LTD
http://jvi.asm.org/
D
ow
nloaded from
 
infection of immune cells, we have now compared the humoral
immune responses elicited by five human SARS-CoV Spike-
based immunogens.
The preparations consisted of either a whole killed SARS-
CoV virion (WKV) or recombinant SARS-CoV Spike proteins
(Fig. 8A) that had been immunopurified from cell lysates or
cell culture supernatants. When compared by ELISA for bind-
ing activity against immobilized-recombinant SARS-CoV
Spike full-length protein, all sera except for the control group
displayed similar binding activity to recombinant Spike (Fig.
8D). Strong neutralizing humoral immune responses against
SARS-CoVpp were detected in sera from animals immunized
with recombinant Spike proteins or whole killed-SARS-CoV
virion (Fig. 8B). Sera elicited by immunization with Ssol and
WKV exhibited the highest neutralizing capabilities with 50%
neutralizing titers of about 1/15,000 and 1/12,000, respectively,
followed by sera immunized with S1 (1/8,000), S (1/4,000), and
S.ECD (1/3,000). As expected, virtually no inhibition of SARS-
CoVpp entry was observed in VeroE6 cells with control serum
from mock-immunized BALB/c mice. When sera were tested
for their ability to trigger ADE, they fell into two distinct
groups (Fig. 8C). Although serum from WKV- and S.ECD-
immunized mice had no effect, Ssol, S1, and S immune sera
triggered the infection of Raji cells. We reasoned that these
differences might have been the consequence of the specific
immune response triggered by the distinct immunogens and
immunization protocols and, therefore, we determined the rel-
ative amount of anti-Spike IgG subclasses of the immune sera
(Fig. 8D). Of note, we observed that the ADE-inducing sera
did not contain anti-Spike IgG2a antibodies, which were pres-
ent in all neutralizing/nonenhancing sera. These results suggest
that the relative amounts of IgG subclass may be involved in
determining the occurrence of antibody-mediated infection of
SARS-CoV.
DISCUSSION
The possibility that an immune response to pathogens may
have also deleterious effects on the host homeostasis has been
the focus of several studies. For example, the hyperinduction
of cytokines following avian influenza virus infection has been
implicated in the severity of the disease (47), and infection of
cells by antibody-dependent enhancement has been known to
occur for several viral diseases (59, 60). We demonstrate here
that anti-Spike antibody potentiates infection of immune cells
by SARS Spike-pseudotyped lentiviral particles and replica-
tion-competent SARS-coronavirus. Antibody-mediated infec-
tion is dependent on one subtype of Fc receptor, FcRII
(CD32). However, ADE mediated by FcRII does not utilize
the endosomal/lysosomal pathway utilized by ACE2-bound vi-
rus, i.e., the common cellular receptor for SARS-CoV in sus-
ceptible cells. Finally, we have found evidence that this ADE
phenomenon is dependent on the immunization strategy used
for candidate vaccines.
We and others (14, 15, 51) reasoned that SARS-CoV Spike
glycoprotein, which has been shown to be responsible for viral
attachment and entry, was a prime target for the development
of SARS vaccines. Because of earlier reports of immune-me-
diated enhancement of coronavirus infection both in vitro (8,
44, 73) and in vivo (65, 68), we investigated this possibility and
reported preliminary data that a neutralizing, anti-Spike im-
mune-serum induced ADE of SARS-CoVpp (30). The effect of
SARS-CoV antiviral antibodies on ADE has been studied in
susceptible cells, but conflicting data have appeared. One
group demonstrated antibody-dependent enhancement of len-
tiviral particles pseudotyped with SARS-CoV Spike variants
detected in palm civets when incubated with rodent (vaccine-
elicited) and convalescent SARS patient-derived monoclonal
antibodies (73). In contrast, another group, using panels of
isogenic SARS-CoV, did not find any evidence of infection
enhancing potential with a series of monoclonal antibodies
(50).
Our experiments conclusively demonstrate with several lines
of evidence that both SARS-CoVpp and replication-compe-
tent SARS-coronavirus infect certain immune cells only in the
presence of anti-Spike immune serum and not in its absence.
Furthermore, we found that homologous anti-Spike immune-
serum never potentiated infection of the permissive epithelial
cell line VeroE6.
In cells infected via the ADE pathway we detected both
SARS-CoV genomic and subgenomic material, as well as the
expression of two viral proteins, N and M. It is believed that an
antibody-mediated infection pathway could provide SARS-
CoV additional entry routes, allowing the virus to broaden its
tropism. Interestingly, early after ADE infection, we detected
far more (ca. 50- to 100-fold) SARS-CoV-positive RNAs com-
pared to its negative strand, a situation found during the pro-
ductive replication of coronaviruses (55) and distinct from the
abortive replication of SARS-CoV reported after direct infec-
tion of macrophages (7). Although we unambiguously illus-
TABLE 2. Primer sequences for RT-PCR detection of human transcripts of FcRs, ACE2, and GAPDHa
FcRs, ACE2,
or GAPDH
Primer sequence (5-3) Expected product size (bp)
Forward Reverse FcR1A FcR2A FcR2B FcR3A FcεR1-chain ACE2 GAPDH
FcR 1A TgTCATgCgTggAAggATAA TCgCACCAgTATAACCCAgAg 413
FcR 2A TTgACAgTTTTgCTgCTgCT AgCCTTCACAggATCAgTgg 702
FcR 2B TTgCCACTgAgAgTgACTgg ATTgTgTTCTCAgCCCCAAC 841
FcR 3A CCTCCCAACTgCTCTg
CTAC
ggTTgACACTgCCAAACCTT 580
FcεR1-chain ggAgAgCCTCAgCTCT
gCTA
TggTggTTTCTCATgCTTCA 198
ACE2 CAAgCAgCTgAggCCATTA ATgCTAgggTCCAgggTTCT 1,190
GAPDH CAATgACCCCTTCATT
gACC
TgCTgTAgCCAAATTCgTTG 866
a All sequences were designed using the Primer 3 Plus web-based application (64).
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trated ongoing infection thanks to the detection of de novo
synthesis of the structural viral proteins N and M, the ADE-
infected Raji cells did not support productive replication of
SARS-CoV. After the initiation of viral gene transcription and
viral protein synthesis, a block appears to occur in the repli-
cation process, ultimately ending in an abortive viral cycle
without the detectable release of progeny virus (12). Whether
ADE occurs in other immune cells and whether such infection
will be abortive remains to be investigated.
Despite not leading to productive infection, it remains of
interest to investigate the functionality and cell fate of ADE
infected cells. Thus, ADE infection induced the initiation of
viral gene transcription—with production of viral gene inter-
mediate species—and viral protein synthesis. Given the ability
of intracellular innate immune sensors, such as the pattern
recognition receptor families TLR and RLH, to detect viral
gene species (2, 69) and the disturbance to the cell homeostasis
caused by SARS-CoV viral proteins (such as 3a protein and
FIG. 5. Blockade of FcRII abrogates antibody-mediated infection of human immune cell lines. (A) Total RNAs from the indicated cell lines
were extracted for RT-PCR amplification as described under Materials and Methods. cDNAs and negative RT controls (RT) were probed for
detection of FcεR1-chain, FcRIA (CD64a), FcRIIA (CD32a), FcRIIB (CD32b), FcRIIIA (CD16a), ACE2, and GAPDH. DNA plasmids
containing the coding sequence of the human Fc receptors or the human ACE2 (104 and 106 copies) were used as positive controls. Amplicons
were visualized by ethidium bromide staining after agarose gel electrophoresis. For reference, a 1-kb molecular-weight standard is also shown. Due
to the murine origin of the macrophage-like P388D1 and J774A.1 cell lines and because the primers were designed for the detection of human
FcR (Table 2), no FcR transcripts were detected in P388D1 and J774A.1 cells. (B) Hematopoietic cell lines displaying a detectable level of FcR
transcript in panel A were subjected to flow cytometry. Cell lines were stained with either isotype-matched control antibody (gray-filled histograms)
or FcR-specific mouse monoclonal antibody (open histograms) as indicated, followed by secondary FITC-conjugated goat anti-mouse antibodies.
Labeled samples were then read by flow cytometry and post-acquisition analysis was performed using FlowJo software. Insets show the median of
fluorescence intensity of the anti-FcR staining. When not visible, the open histograms were superimposed on the gray-filled ones. The data are
representative of two independent experiments with similar results. (C) Effect of FcR blockage on susceptibility of the cells to ADE infection.
Prior to infection, cells were treated with anti-FcR blocking antibodies. At 3 days postinfection, luciferase substrate reagent was added to wells,
and the luminescence was measured. The data were normalized to control conditions, viz., cells infected in the presence of IgG isotype-matched
control antibody, and expressed as a percentage of the changes in luminescence. For all conditions, values of background luminescence (never
exceeding 3% of control) were subtracted prior to normalization. The results are the means  the SD of nine measurements from three
independent experiments. ‡, P  0.05; *, P  0.001 (unpaired Student t test).
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SARS-unique domain) (5, 36, 63), a possible participation of
immune-mediated enhanced disease during SARS pathogene-
sis cannot be ruled out. Of note, clinical observations have
already reported poor disease outcomes in early seroconverted
SARS patients (22, 37, 76).
The observation of a change of tropism of SARS-CoV in the
presence of antiviral immune serum distinguishes the ADE of
SARS-CoV infection from many other examples of antibody-
mediated viral infection, where the presence of antiviral anti-
bodies increases the viral load due to infection of a higher
number of already-susceptible cells (59, 60). Of note, a shift of
tropism from epithelial to immune cells, albeit mediated by a
different mechanism, was associated with an increased severity
of disease during the course of lethal coronavirus-induced fe-
line infectious peritonitis (52).
FcR blocking experiments clearly demonstrate the involve-
ment of FcRII in the occurrence of ADE infection of Raji
and Daudi cells. Since both anti-FcRI and anti-FcRII treat-
ments, however, had an impact on the occurrence of ADE
infection of THP-1 cells, no firm conclusion could be drawn as
for the possible contribution of FcRI. Due to the coexpres-
sion of the two FcR in this cell line (cf. Fig. 5B, where100%
FIG. 6. Human FcRIIA and B1, but not huFcRIA nor huFcRIIIA, are responsible for ADE of SARS-CoV pseudoparticles (SARS-CoVpp)
infection. (A) Human Raji, parental, and monoclonal FcR-transduced human ST486 B cell lines were stained with either isotype-matched control
antibody (gray-tinted histogram) or FcR-specific mouse monoclonal antibody (open histogram) as indicated, followed by secondary FITC-
conjugated goat anti-mouse antibodies. Labeled samples were then read by flow cytometry and postacquisition analysis was performed using
FlowJo software. The inset shows the median of fluorescence intensity of the anti-FcR staining. When not visible, the open histograms were
superimposed on the gray-filled ones. (B) Potency of FcR(s) to trigger antibody-mediated entry of SARS-CoVpp was assessed by using ST486
cell lines stably expressing a single FcR. SARS-CoVpp were incubated in the presence or absence of different dilutions (1/1,000, 1/2,000, and
1/4,000) of either control (solid bars) or anti-Spike (hatched bars) serum for 1 h prior to addition to the cells. At 3 days postinfection, luciferase
substrate reagent was added to wells, and the luminescence was measured. The data were normalized to control conditions, viz., cells incubated
with SARS-CoVpp in the absence of any serum (black bar, taken as unity) and expressed as fold changes in luminescence. Because results for
SARS-CoVpp  control serum were virtually identical with all cell lines, for the sake of clarity only one dilution (1/4,000) is shown. The results
are the means  the SD of nine measurements from three independent experiments. Statistical significance was assessed by comparing the
appropriate dilutions of mock and anti-Spike serum. ‡, P  0.05; *, P  0.01 (unpaired Student t test).
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of the cells expressed FcRI and FcRII), blocking antibodies
could indeed bind not only to the targeted FcR via their Fab
portions but also to other FcR via their Fc portions. Thus, for
example, mouse IgG1 anti-FcRI antibody could bind specif-
ically to FcRI via its Fab portions and to FcRII via its Fc
portion, making both FcR unavailable for interacting with
opsonized pseudoparticles.
On the basis of these results, we decided to undertake a
systematic analysis of the individual role of the human Fc
receptors subfamilies. Our experiments demonstrate that only
FcRIIA and, to a lesser extent, FcRIIB1 triggered infection
by SARS-CoVpp in the presence of anti-Spike serum. These
results extend our observations with FcR-blocking antibodies
in Raji cells (30) because only FcRII, but not FcRI or
FcRIII, is found in that cell line. However, in light of the IgG
composition of the anti-Spike immune serum used in the pres-
ent study and of the inability of FcRI and FcRIII to bind
mouse IgG1 (10), further investigations are required to for-
mally rule out the involvement of these receptors in triggering
ADE of SARS.
Despite these results suggesting an important role of the
FcRII family in the occurrence of ADE of SARS-CoV, our
conclusion has to be qualified by the observation that other
human immune cell lines (such as K-562, U-937, MT4-R5, and
721.221) that also have detectable cell surface expression of
FcRII by flow cytometry are refractory to ADE infection. The
ability of those cell lines to bind SARS-CoVpp/anti-Spike im-
mune complexes is now under investigation. If binding and/or
internalization occurs, it would also be of interest to ensure
that failure of infection is not due to inability of the viral
particles to uncoat/initiate replication in those cells. Finally, in
order to define more precisely the mechanism underlying the
susceptibility of immune cells to antibody-mediated SARS-
CoV infection, a better understanding of the events down-
stream binding of the immune complexes to the Fc receptors is
needed.
Viral glycoproteins typically mediate attachment, fusion,
and entry by one of two mechanisms. Some viruses, such as
HIV, infect mainly through a pH-independent entry process
(fusion occurring at the plasma membrane), whereas other
viruses, such as influenza, utilize a pH-dependent endocytic
pathway (31). It has been demonstrated that, following binding
FIG. 7. Antibody-mediated infection is independent of acidic pH and cysteine-protease activity of the endosomal/lysosomal compartment. (A,
C, and D) pH and protease requirements for ACE2- versus antibody-mediated entry of SARS-CoVpp were investigated with different pharma-
cological treatments. Prior to infection, VeroE6 and Raji cells were preincubated with the indicated concentrations of ammonium chloride
(NH4Cl) (A) for 1 h or the cysteine protease inhibitor E-64d (C) and cathepsin L inhibitor III (D) for 3 h. SARS-CoVpp, with or without anti-Spike
serum (1/2,000), were then added to the cells in the continuous presence of the drugs. At 3 days postinfection, luciferase substrate reagent was
added to wells, and the luminescence was measured. The data were normalized to the appropriate control conditions (taken as unity) with
SARS-CoVpp with or without anti-Spike serum for Raji and VeroE6 cells, respectively. The results are shown as means  the SD of nine
measurements from three independent experiments. Statistical differences between VeroE6 and Raji cells were assessed by the unpaired Student
t test. **, P  0.005. (B) Cell surface expression of FcRII on Raji cells after NH4Cl treatment. Cells were incubated with the indicated
concentrations of the drug for 1, 3, and 5 h, labeled with anti-huFcRII antibody, and subjected to flow cytometry. The data were normalized to
the mean fluorescence intensity of controls (no drug). The results are shown as means  the SD of six measurements from two independent
experiments. When not visible, the SD values were contained within the size of the symbols.
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to its ACE2 receptor, SARS-CoV entry into susceptible cells
occurs via pH-dependent endocytosis (24, 71), although Spike
protein can also induce cell fusion at a neutral pH (40, 57).
More recently a crucial activity of the lysosomal cysteine pro-
tease cathepsin L for an efficient infection by SARS-CoV has
been uncovered (26, 56). In contrast, our results indicate that
Fc receptor-mediated infection is not dependent on either
endosomal acidic pH or the activity of cysteine proteases.
A striking observation was the opposite outcome of the
ACE2- versus FcR-mediated infection subsequent to neutral-
ization of the endosomal acidic pH. Whereas infection of
VeroE6 cells was completely inhibited by NH4Cl, as previously
described (24, 71), the same treatment triggered an approxi-
mately 2- to 4-fold increase in ADE infection. The exacerba-
tion of the antibody-mediated infection in the presence of
NH4Cl is not due to a higher cell surface expression of the
FcRII, which was actually slightly decreased. A likely expla-
nation for our results would be that most of the viral particles
that enter cells through ADE pathway remain trapped in an
acidic compartment and are eventually degraded. The inhibi-
tion of endosomal acidification prevents their degradation and
grants them opportunity to accumulate and more efficiently
infect cells upon removal of the drug at 7 h postinfection.
Alternatively, the ability of Spike to mediate cell membrane
fusion at neutral pH (40, 57), could allow more antibody-
opsonized SARS-CoVpp to fuse with the endosomal mem-
branes. Such a mechanism has already been observed with a
poorly infectious HIV strain, which exhibited greatly enhanced
infectivity under conditions where endosomal pH was neutral-
ized (16, 67). Taken together, our results demonstrate that the
biochemical requirements of FcR-mediated infection are
markedly distinct from those underlying ACE2-dependent en-
try and illustrate a novel mechanism by which SARS-CoV can
enter into target cells.
The emergence of SARS in late 2002, which resulted in
significant human and economic losses, highlighted the lack of
antiviral strategies to control coronavirus infections. Given the
continuous presence of SARS-CoV related agents in the envi-
ronmental reservoir, vaccination remains a major option for
preventing resurgence of SARS in humans, especially individ-
uals at highest risk in the case of an outbreak (i.e., healthcare
workers). Some vaccines against animal coronaviruses have
been successfully generated, but their development has proven
very difficult due to immune enhancement of disease in vacci-
nated recipients (28, 53, 65).
We have evaluated, therefore, the neutralizing versus en-
assay). At 3 days postinfection, luciferase substrate reagent was added
to the wells, and the luminescence was measured. Five independent
experiments were performed in triplicates, and data are presented as
the means  the SD of a representative experiment. (D) IgG compo-
sition of the immune serum of mice vaccinated with the indicated
immunogens. The binding activity toward immobilized recombinant
SARS-CoV Spike protein of pooled serum (1/2,000 dilution) was mea-
sured by ELISA, and bound IgGs were revealed with specific poly-
clonal secondary antibodies. A representative result from three inde-
pendent experiments is shown. The results are expressed as means 
the SD of triplicate measurements. When not visible, the SD values
were contained within the size of the symbols.
FIG. 8. Occurrence of ADE of SARS-CoV infection after immu-
nization with different vaccine candidates. (A) Schematic illustration
of the different forms of recombinant SARS-CoV Spike protein used
for vaccination of BALB/c mice. Positions of the different regions are
indicated according to Swiss-Prot accession no. P59594. (B and C)
Neutralizing and enhancing abilities of antisera elicited after immuni-
zation with different SARS vaccine candidates. SARS-CoVpp were
incubated in the presence of a 2-fold serial dilution (1/1,1000 to
1/16,000) of either control or anti-Spike serum for 1 h prior to addition
to VeroE6 cells (B) (neutralization assay) or Raji cells (C) (ADE
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hancing capabilities of 5 different SARS vaccine formulations.
Our results show that ADE was dependent on the immuniza-
tion strategy with two of five candidate vaccines displaying
obvious neutralizing capabilities without triggering SARS-
CoVpp entry into immune cells. It is not clear why the other
three formulations induced ADE while showing similar neu-
tralizing potencies. We can rule out the lack of recognition/
binding to SARS-CoVpp, since all tested sera displayed a clear
dose-dependent neutralization of the viral particles over at
least four serial dilutions. Furthermore, the total IgG content
was comparable among the immunized cohorts, except for the
control group that, as expected, had a lower amount (data not
shown).
In the FCoV model, ADE has been linked to both neu-
tralizing and non-neutralizing antibodies (8). In our exper-
iments we have observed that, among sera causing ADE
there was a direct correlation between the neutralization
titer and the enhancing capability. Because anti-SARS-CoV
Spike sera were able to both neutralize SARS-CoVpp in-
fection and bind native recombinant full-length Spike pro-
tein with similar potency (i.e., Ssol  WKV 

 S1 
 S 
S.ECD), we speculate that vaccination with a given immuno-
gen did not induce a marked bias in eliciting non-neutral-
izing anti-Spike IgGs. However, we cannot exclude that vari-
ations in the ratio of neutralizing versus non-neutralizing
epitopes between vaccine preparations could have an impact
on the occurrence of ADE.
Because a single class of anti-FCoV Spike antibodies (i.e.,
IgG2a) has been demonstrated to play a crucial role in initia-
tion of ADE (8, 25), we have investigated the relative amount
of anti-Spike IgG1 and IgG2a in our mouse sera. Interestingly,
none of the ADE-inducing sera contained anti-Spike IgG2a
antibodies, whereas the two neutralizing/nonenhancing sera
did. Further experiments are needed to understand why a
markedly distinct polarization of the immune response was
achieved with highly related SARS-CoV Spike immunogens
and whether absence of IgG2a is causally related to the occur-
rence of ADE infection.
Recently, allelic polymorphism of the human FcRIIA
has been incriminated as a risk factor for developing severe
SARS pathology (75). The authors of that study found that
individuals harboring the R/R131 genotype were more likely
to develop severe SARS pathology than were their H/H131
counterparts. The R/R131 form of FcRIIA can bind to
both IgG1 and IgG2a, whereas H/H131 can only bind to
IgG2a (48, 54). However, in our transduction experiments
using B cell clones stably expressing a single polymorphic
FcRIIA, both allelic variants were able to trigger ADE of
SARS-CoVpp.
It is usually agreed that infection by SARS-CoV is not only
confined to the respiratory tract but also involves the gastro-
intestinal tract and other organ systems. Several reports have
highlighted the direct infection of hematopoietic cells by
SARS-CoV (19, 39, 74); however, it is not yet clear how SARS-
CoV gets a foothold into immune cells, which do not express
the SARS-CoV receptor ACE2 (20, 21). Antibody-mediated
infection, in addition to other alternative entry routes, such as
L-SIGN or DC-SIGN (29, 71), may provide SARS-CoV with
an opportunity to broaden its target options. Interestingly,
antibody-mediated infection has been shown to elicit markedly
distinct responses compared to viral entry through the natural
host receptor (23, 45, 58, 62). Indeed, antibody-mediated in-
fection of feline coronavirus not only enhances viral progeny
but also dramatically increases production of tumor necrosis
factor alpha by infected cells. The hyperinduction of the pro-
inflammatory cytokine is believed to account for the exacer-
bated apoptosis of the neighboring leukocytes (61, 62). Simi-
larly, ADE of Ross river virus has been shown to facilitate viral
replication by disrupting transcription of antiviral type I inter-
ferons (58). Because it has been hypothesized that deregula-
tion of host cytokine/chemokine responses is a hallmark of
SARS (7, 27, 35, 43, 70), it would be interesting to investigate
how ADE of SARS-CoV infection may contribute to the dis-
ease pathogenesis.
Altogether, our results report a novel mechanism by
which SARS-CoV can enter into target cells that do not
express the conventional virus receptor and are otherwise
refractory to the virus. This may have implications for un-
derstanding the tropism and pathogenesis of the virus and
highlight potential pitfalls associated with immunization
against this coronavirus. These findings should prompt fur-
ther investigations for a better understanding of the molec-
ular and cellular mechanisms underlying ADE of SARS-
CoV infection. The consequences of this alternative
infection pathway on the functionality and/or homeostasis of
the target cells also need to be resolved.
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